Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

Recruiting now · Phase 2

Conditions studied: Lung Cancer, Lung Cancer Stage I, Lung Cancer Stage II

In brief

This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.

Key facts

Study ID

NCT03290534

Run by

CivaTech Oncology

People needed

40

Starts

2019-03-13

Expected to finish

2027-12-01

Last updated by the study team

2025-04-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject signed inform consent
• Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung
• Pre-operative criteria
• Lung nodule suspicious for NSCLC
• Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen
• Clinical stage I or Clinical stage II
• Not pregnant or nursing
• Negative pregnancy test in premenopausal women
• Fertile patients must use effective contraception
• More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer

Where it is running

• NYU Langone Health — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.